Cargando…
Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
BACKGROUND: Reports of local and systemic side-effects of COVID-19 vaccination may play an important role in public confidence in the acceptance of the COVID-19 vaccine booster dose. METHODS: We conducted a retrospective cross-sectional study among adults living in Eastern Province of Saudi Arabia....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568279/ https://www.ncbi.nlm.nih.gov/pubmed/36276167 http://dx.doi.org/10.1016/j.infpip.2022.100251 |
_version_ | 1784809608982822912 |
---|---|
author | Al-Matouq, Jenan Ahmed Ali, Mohammad Daud Al-Somali, Samiah Mohammad Ahmad, Ayaz Banu, Nuzhat Patel, Munfis |
author_facet | Al-Matouq, Jenan Ahmed Ali, Mohammad Daud Al-Somali, Samiah Mohammad Ahmad, Ayaz Banu, Nuzhat Patel, Munfis |
author_sort | Al-Matouq, Jenan Ahmed |
collection | PubMed |
description | BACKGROUND: Reports of local and systemic side-effects of COVID-19 vaccination may play an important role in public confidence in the acceptance of the COVID-19 vaccine booster dose. METHODS: We conducted a retrospective cross-sectional study among adults living in Eastern Province of Saudi Arabia. A link to the survey was distributed to community members via WhatsApp, SMS, or e-mail. Participants' general and demographic information was also collected, as well as information about any local and systemic side-effects reported following vaccination. RESULTS: A total of 370/390 (94.87%) of respondents reported one or more side-effects. Pain or redness at the site of injection (88.92%), fatigue (43.78%), body pain fever (37.84%), and headache (15.95%) were the most commonly reported side-effects. Moreover, 2.43% of the participants reported side-effects needed to see a physician; only four were admitted to the hospital. The non-healthcare respondents (n=273 (97.15%), OR (95% CI) = 5.22 (2.02, 13.48, P <0.001) were more likely to report side-effects compared to the healthcare related respondents (n=36 (85.71%), OR (95% CI) = 0.25 (0.10, 0.70), P=0.013). CONCLUSION: According to this study, the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine was safe when given to Saudi Arabian adults. All reported side-effects were mild to moderate. The findings will likely persuade vaccine-hesitant individuals and pessimists to accept booster dose of COVID-19 vaccine. |
format | Online Article Text |
id | pubmed-9568279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95682792022-10-16 Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia Al-Matouq, Jenan Ahmed Ali, Mohammad Daud Al-Somali, Samiah Mohammad Ahmad, Ayaz Banu, Nuzhat Patel, Munfis Infect Prev Pract Original Research Article BACKGROUND: Reports of local and systemic side-effects of COVID-19 vaccination may play an important role in public confidence in the acceptance of the COVID-19 vaccine booster dose. METHODS: We conducted a retrospective cross-sectional study among adults living in Eastern Province of Saudi Arabia. A link to the survey was distributed to community members via WhatsApp, SMS, or e-mail. Participants' general and demographic information was also collected, as well as information about any local and systemic side-effects reported following vaccination. RESULTS: A total of 370/390 (94.87%) of respondents reported one or more side-effects. Pain or redness at the site of injection (88.92%), fatigue (43.78%), body pain fever (37.84%), and headache (15.95%) were the most commonly reported side-effects. Moreover, 2.43% of the participants reported side-effects needed to see a physician; only four were admitted to the hospital. The non-healthcare respondents (n=273 (97.15%), OR (95% CI) = 5.22 (2.02, 13.48, P <0.001) were more likely to report side-effects compared to the healthcare related respondents (n=36 (85.71%), OR (95% CI) = 0.25 (0.10, 0.70), P=0.013). CONCLUSION: According to this study, the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine was safe when given to Saudi Arabian adults. All reported side-effects were mild to moderate. The findings will likely persuade vaccine-hesitant individuals and pessimists to accept booster dose of COVID-19 vaccine. Elsevier 2022-10-15 /pmc/articles/PMC9568279/ /pubmed/36276167 http://dx.doi.org/10.1016/j.infpip.2022.100251 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Article Al-Matouq, Jenan Ahmed Ali, Mohammad Daud Al-Somali, Samiah Mohammad Ahmad, Ayaz Banu, Nuzhat Patel, Munfis Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia |
title | Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia |
title_full | Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia |
title_fullStr | Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia |
title_full_unstemmed | Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia |
title_short | Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia |
title_sort | prevalence of side-effects associated with the booster dose of pfizer-biontech (bnt162b2) of covid-19 vaccine among vaccinated adults in the eastern province of saudi arabia |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568279/ https://www.ncbi.nlm.nih.gov/pubmed/36276167 http://dx.doi.org/10.1016/j.infpip.2022.100251 |
work_keys_str_mv | AT almatouqjenanahmed prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia AT alimohammaddaud prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia AT alsomalisamiahmohammad prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia AT ahmadayaz prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia AT banunuzhat prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia AT patelmunfis prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia |